Stock Events

Stock Events

Hemostemix 

€0.04
0
+€0+0% Today

Statistics

Day High
0.04
Day Low
0.04
52W High
0.09
52W Low
0.04
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2VF0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is involved in the development of drugs and therapies, including those in the regenerative medicine space, competing with Hemostemix's stem cell therapies.
Novartis
NVS
Mkt Cap297.32B
Novartis focuses on innovative medicines and directly competes in the regenerative medicine sector, offering alternatives to Hemostemix's solutions.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that develops treatments for various conditions, including those that could compete with stem cell therapies offered by Hemostemix.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and has interests in developing treatments that could compete with Hemostemix's stem cell-based therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in creating new therapies, including those in the regenerative medicine area, potentially competing with Hemostemix.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics works on genomic therapies, including gene editing, a field that competes with stem cell therapy approaches like those of Hemostemix.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on gene editing, a revolutionary approach that competes with traditional stem cell therapies offered by Hemostemix.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine is involved in gene editing, directly competing with the stem cell therapy market that Hemostemix is part of.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is another key player in the gene editing space, offering competitive alternatives to stem cell-based therapies like those developed by Hemostemix.

About

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Show more...
CEO
Mr. Thomas A. Smeenk B.A., BA Hons
Employees
12
Country
US
ISIN
CA4236943060

Listings

STU
DE
2VF0.STU
OTC Link
US
HMTXF
V
CA
HEM.V
F
DE
2VF0.F

0 Comments

Share your thoughts

FAQ

What is Hemostemix stock price today?▼
The current price of 2VF0.STU is €0.04 EUR — it has increased by +0% in the past 24 hours. Watch Hemostemix stock price performance more closely on the chart.
What is Hemostemix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Hemostemix stocks are traded under the ticker 2VF0.STU.
Is Hemostemix stock price growing?▼
2VF0.STU stock has fallen by -1.37% compared to the previous week, the month change is a -22.58% fall, over the last year Hemostemix has showed a -32.71% decrease.
How many employees does Hemostemix have?▼
As of April 10, 2026, the company has 12 employees.
In which sector is Hemostemix located?▼
Hemostemix operates in the Health Care sector.
When did Hemostemix complete a stock split?▼
Hemostemix has not had any recent stock splits.
Where is Hemostemix headquartered?▼
Hemostemix is headquartered in Calgary, US.